Ziarco Appoints Pablo Jimenez as Chief Medical Officer

Ziarco Group, a clinical-stage biopharmaceutical company focusing on inflammatory skin diseases, has named Pablo Jimenez as chief medical officer. Dr. Jimenez will oversee the clinical development of Ziarco’s programs targeting conditions such as atopic dermatitis and psoriasis.

“Dr. Jimenez has an impressive track record as both a physician and a senior pharmaceutical executive,” said Mike Yeadon, president and chief executive officer of Ziarco. “His clinical development and regulatory affairs expertise will be very important as we advance our lead compounds, ZPL-389 and ZPL-521, through clinical studies. Furthermore, his deep knowledge of dermatology significantly strengthens the Ziarco team, complementing our existing R&D and mechanism expertise.”

Dr. Jimenez brings to Ziarco more than 20 years of clinical development and medical affairs experience in therapeutic areas including dermatology, respiratory, and wound healing. Most recently, he served as chief medical officer and executive vice president at Celsus Therapeutics, where he led global clinical development of the company’s pipeline of inflammatory disease therapies.